var data={"title":"South American bartonellosis: Oroya fever and verruga peruana","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">South American bartonellosis: Oroya fever and verruga peruana</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/contributors\" class=\"contributor contributor_credentials\">David H Spach, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/contributors\" class=\"contributor contributor_credentials\">Ciro P Maguina, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/contributors\" class=\"contributor contributor_credentials\">Eloy E Ordaya, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/contributors\" class=\"contributor contributor_credentials\">Stephen B Calderwood, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 26, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>South American bartonellosis, or Carrion's disease, is an infection caused by <em>Bartonella bacilliformis</em> that is transmitted by phlebotomine sand flies. Typically, this condition has been considered a biphasic illness characterized by an initial febrile phase, known as Oroya fever, followed by a secondary phase characterized by development of skin lesions, known as verruga peruana. Subsequently, however, variable clinical patterns associated with this infection have been observed, ranging from asymptomatic bacteremia to fulminant illness [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>Issues related to <em>B. bacilliformis </em>will be reviewed here; issues related to infection caused by other <em>Bartonella</em> species are discussed separately. (See related topics.)</p><p class=\"headingAnchor\" id=\"H14405285\"><span class=\"h1\">HISTORY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is evidence from pre-Columbian artifacts that the cutaneous form of the disease was present in South America at least 1000 years prior to the arrival of Europeans [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/3\" class=\"abstract_t\">3</a>]. During the Inca era, the disease was called &quot;Sirki,&quot; which means &quot;warts in blood.&quot;</p><p>In 1885, Daniel Alcides Carri&oacute;n, a Peruvian medical student, demonstrated that the two phases of illness are caused by the same organism, via self-inoculation with infectious skin lesion material from a patient with verruga peruana; soon thereafter, he developed a fatal infection with fever and severe anemia. As a tribute to him, the disease is also known as Carrion's disease [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H6660551\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Carrion's disease is endemic to the &quot;verruga zone,&quot; a region in the Andes Mountains of Peru, Colombia, and Ecuador [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/2\" class=\"abstract_t\">2</a>]. Sporadic cases have been reported from Bolivia, Chile, and Guatemala [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/5\" class=\"abstract_t\">5</a>].</p><p><em>B. bacilliformis</em> is transmitted by the bite of the female sand fly of the genus <em>Lutzomyia</em> spp. The vector typically lives 500 to 3200 meters (1600 to 10,500 feet) above sea level and has nocturnal feeding behavior [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/1\" class=\"abstract_t\">1</a>]; <em>Lutzomyia verrucarum</em> is the most effective vector in Peru [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/6\" class=\"abstract_t\">6</a>]. Some outbreaks in nonendemic areas have been associated with other species of <em>Lutzomyia</em>, such as <em>L. maranonensis</em>, <em>L. robusta</em>, and <em>L. peruensis</em>, denoting the potential of the vector to adapt to other climates and spread disease to other regions [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/7-9\" class=\"abstract_t\">7-9</a>]. Humans are the principal hosts; no reservoir of <em>B. bacilliformis</em> has been identified in any domestic or wild animal.</p><p>Oroya fever occurs most frequently among tourists and transient workers who are immunologically na&iuml;ve to <em>B. bacilliformis</em>, whereas verruga peruana occurs most frequently among individuals native to the verruga zone. In one cohort study in an endemic region of Peru, the incidence in the general population was 12 cases per 100 person-years, with a breakdown of clinical manifestations as follows [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/10\" class=\"abstract_t\">10</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oroya fever (11 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Verruga peruana and a recent febrile illness suggestive of Oroya fever (37 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Verruga peruana without a recent febrile illness (32 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Asymptomatic infection (21 percent)</p><p/><p>Infection occurred most frequently among children &lt;5 years of age (38 cases per 100 person-years), and there was a linear decrease in incidence with increasing age. Clustering of cases was also observed; 70 percent of cases occurred in 18 percent of households.</p><p>Underreporting can occur in the setting of mild infection. One series of 11 patients with chronic verrucous skin lesions was described in a coastal, lowland region of Ecuador [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/11\" class=\"abstract_t\">11</a>]. Serologic study of more than 200 individuals in the surrounding region noted 21 percent seropositivity among contacts of index cases.</p><p>Vertical transmission of <em>B. bacilliformis</em> to a newborn whose mother had febrile illness in the third trimester of pregnancy has been described [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/12\" class=\"abstract_t\">12</a>].</p><p>Climate change has been associated with increases in the incidence of bartonellosis in Peru, as occurred during the El Ni&ntilde;o events of 1986 to 1988 and 1997 to 1998 [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/13,14\" class=\"abstract_t\">13,14</a>].</p><p class=\"headingAnchor\" id=\"H14405321\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>B. bacilliformis</em> was the first <em>Bartonella</em> organism identified as a human pathogen. It is an intracellular, pleomorphic, gram-negative bacterium that is the recognized causative organism of Oroya fever and verruga peruana.</p><p>It is possible that some illnesses previously attributed to <em>B. bacilliformis</em> are due to a subsequently recognized <em>Bartonella</em> species, <em>Bartonella rochalimae</em>; this organism was isolated from an American tourist who presented with fever, splenomegaly, anemia, and a history of insect bites after a trip to Peru that included travel to a region in which <em>B. bacilliformis</em> is endemic [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/15\" class=\"abstract_t\">15</a>]. Studies performed in endemic and nonendemic areas for <em>B. bacilliformis </em>have demonstrated <em>B. rochalimae</em> infection in asymptomatic dogs as well as in fleas from cats and guinea pigs; these findings support the potential zoonotic transmission of this pathogen [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/16,17\" class=\"abstract_t\">16,17</a>].</p><p>Another <em>Bartonella</em> species, <em>Bartonella ancashensis,</em> was identified in 2003 during an antibiotic treatment trial of patients with verruga peruana; two patients were infected with a <em>Bartonella</em> species distinct from any known <em>Bartonella</em> species, and molecular analysis identified a new species that is phylogenetically similar to <em>B. bacilliformis</em> [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/18-20\" class=\"abstract_t\">18-20</a>].</p><p class=\"headingAnchor\" id=\"H14405361\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>B. bacilliformis</em> induces alterations in the immune system in its attempt to evade the host immune response and establish persistent infection. In the acute phase, the organism causes a substantial increase in interleukin-10 secretion by erythrocytes, which attenuates cytokine production and suppresses the function of certain immune cells, including T helper cells, macrophages, and dendritic cells [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/21,22\" class=\"abstract_t\">21,22</a>]. This perturbation in host immune function favors persistent B<em>. bacilliformis</em> infection and creates an immune state that is more vulnerable to secondary infection with bacterial pathogens. During the chronic form, there are high levels of interferon-gamma and interleukin-4 [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/23\" class=\"abstract_t\">23</a>].</p><p>It was previously believed that <em>B. bacilliformis</em> was the only <em>Bartonella </em>with multiple unipolar flagella; this characteristic provides it with a unique mechanism to enter erythrocytes. Subsequently, multiple unipolar flagella have been observed in other <em>Bartonella</em> species, including <em>B. rochalimae</em>, <em>B. schoenbuchii</em>, and <em>B. clarridgeiae</em> [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/15,24,25\" class=\"abstract_t\">15,24,25</a>]. Other organisms lacking these flagella are capable of entering red blood cells via other mechanisms.</p><p>In the chronic form of disease, the bacterium invades endothelial cells, forms Rocha-Lima inclusion bodies, and stimulates endothelial proliferation and angiogenesis, producing hypervascular nodules. Similar events occur in the setting of infection due to other <em>Bartonella</em> species that cause bacillary angiomatosis [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/26\" class=\"abstract_t\">26</a>]. (See <a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-bartonella-infections-in-hiv-infected-patients#H2\" class=\"medical medical_review\">&quot;Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients&quot;, section on 'Bacillary angiomatosis'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infection with <em>B. bacilliformis</em> causes an acute febrile illness, Oroya fever, and a secondary phase with chronic cutaneous manifestations, verruga peruana [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/27,28\" class=\"abstract_t\">27,28</a>]. Other clinical presentations may also occur, including asymptomatic or chronic bacteremia, verruga peruana without Oroya fever, or recurrent verrucous illness; serologic surveys indicate that as many as 56 percent of seropositive individuals have asymptomatic infection [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/29\" class=\"abstract_t\">29</a>]. In addition, many patients who develop verruga peruana lesions do not recall a history of febrile illness in the preceding three months [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/10,28\" class=\"abstract_t\">10,28</a>]. The incubation period of South American bartonellosis is 1 to 30 weeks (mean 8 weeks) [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Acute phase (Oroya fever)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The acute, or hematic, phase generally begins with insidious onset of mild fever, headache, anorexia, and malaise [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/27\" class=\"abstract_t\">27</a>]. In one review including 145 patients with bartonellosis, the most common clinical features were fever, pallor, malaise, painless hepatomegaly, and lymphadenopathy [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/28\" class=\"abstract_t\">28</a>]. Anemia develops due to parasitic infection of red blood cells and cells of the reticuloendothelial system, with subsequent clearance of parasitized cells from the circulation [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/30\" class=\"abstract_t\">30</a>]. The acute phase lasts two to four weeks, and the majority of patients who receive treatment recover; progression to the eruptive phase occurs after weeks or months in less than 5 percent of cases.</p><p>In the absence of antimicrobial therapy, mortality can reach 90 percent; when treatment is started early, mortality is generally less than 10 percent [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/28\" class=\"abstract_t\">28</a>]. Factors associated with poor prognosis include the presence of anasarca, petechiae, and altered mental status [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/28\" class=\"abstract_t\">28</a>]. Other risk factors associated with increased mortality include age &gt;45 years, history of alcohol use, and presentation with shock, pulmonary edema, pericarditis, seizures, or coma [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/31\" class=\"abstract_t\">31</a>].</p><p>Acute phase secondary complications are common, as discussed in the following section.</p><p class=\"headingAnchor\" id=\"H6660793\"><span class=\"h3\">Complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infectious <span class=\"nowrap\">and/or</span> noninfectious complications occur in up to 70 percent of patients with Oroya fever.</p><p>Infectious complications include secondary infection with <em>Salmonella</em> (<em>typhi</em> and non-<em>typhi</em>), <em>Shigella dysenteriae</em>, <em>Staphylococcus aureus</em>, <em>Klebsiella</em> spp, <em>Enterobacter</em> spp, <em>Candida</em> spp, toxoplasmosis reactivation, disseminated histoplasmosis, <em>Pneumocystis jirovecii</em> pneumonia, leptospirosis, and malaria due to <em>Plasmodium vivax</em> [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/28,32-34\" class=\"abstract_t\">28,32-34</a>]. Apart from hemolytic anemia associated with <em>Bartonella</em> described earlier, other hematological syndromes include disseminated intravascular coagulation, autoimmune hemolytic anemia, hemophagocytic syndrome, and thrombocytic purpura [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/35\" class=\"abstract_t\">35</a>].</p><p>Noninfectious complications include anasarca, neurologic manifestations, ocular compromise, and cardiovascular complications [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/28\" class=\"abstract_t\">28</a>]. In one study including 68 patients with Oroya fever in Peru, cardiovascular complications were observed in 53 percent of cases; the investigators reported a range of cardiovascular complications [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/36\" class=\"abstract_t\">36</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Heart failure &ndash; 91 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pericardial effusion &ndash; 44 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary edema &ndash; 36 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cardiogenic shock &ndash; 17 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cardiac tamponade &ndash; 11 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Myocarditis &ndash; 11 percent</p><p/><p>In addition, a single case of acute endocarditis due to <em>B. bacilliformis</em> in a child with congenital coronary artery-to-right ventricular fistula was described in an observational study of children with Oroya fever [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/32\" class=\"abstract_t\">32</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Eruptive phase (verruga peruana)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The eruptive, or verruga, phase occurs after organisms invade capillary endothelial cells and induce cellular proliferation, producing hemangioma-like nodules in the skin and mucous membranes [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/27\" class=\"abstract_t\">27</a>]. Verruga peruana can appear two to eight weeks after the patient has apparently recovered from Oroya fever [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/3,37\" class=\"abstract_t\">3,37</a>]. However, most patients with verruga peruana do not have an antecedent history of febrile illness.</p><p>There are three major types of skin lesions: miliary, nodular, and mular [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Miliary lesions are small (less than 3 mm), round, soft, reddish pinpoint papules clustered in crops that are confined to the papillary dermis (<a href=\"image.htm?imageKey=ID%2F66284\" class=\"graphic graphic_picture graphicRef66284 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/30,37\" class=\"abstract_t\">30,37</a>]. Untreated, these lesions can progress to the nodular phase.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mular lesions are nodular lesions that evolve into larger (&gt;5 mm) lesions (<a href=\"image.htm?imageKey=ID%2F76799\" class=\"graphic graphic_picture graphicRef76799 \">picture 2</a>). These lesions are highly vascular, bulbous, tend to bleed easily, and can ulcerate.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nodular lesions are nontender wart-like lesions that may become pedunculated (<a href=\"image.htm?imageKey=ID%2F60673\" class=\"graphic graphic_picture graphicRef60673 \">picture 3</a>). Some subcutaneous lesions become apparent with a purplish color on the skin surface as they push upward, thinning the overlying skin.</p><p/><p>Lesions usually develop on the skin but can also involve mucous membranes. Lesions of more than one type may occur simultaneously in a given patient [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/37\" class=\"abstract_t\">37</a>]. In the absence of antimicrobial therapy, lesions may persist for months or years. Patients with verruga peruana often have concomitant systemic symptoms like fever, malaise, or osteoarticular pain [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/28\" class=\"abstract_t\">28</a>].</p><p>As lesions regress, they become more pale because of diminished vascularization. There may be some residual hyperpigmentation, but scarring does not usually occur. Recurrence of verrucous lesions has also been described. Mortality in the eruptive phase is very low [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/38\" class=\"abstract_t\">38</a>].</p><p>The verruga lesions are formed by proliferation of capillaries and endothelial cell hyperplasia and are similar to those seen in cutaneous bacillary angiomatosis and Kaposi's sarcoma. (See <a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-bartonella-infections-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=aids-related-kaposi-sarcoma-staging-and-treatment\" class=\"medical medical_review\">&quot;AIDS-related Kaposi sarcoma: Staging and treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16718024\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of Oroya fever is established by blood culture or by identification of <em>B. bacilliformis</em> organisms on a Giemsa-stained blood smear (<a href=\"image.htm?imageKey=ID%2F58621\" class=\"graphic graphic_picture graphicRef58621 \">picture 4</a>) [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/37\" class=\"abstract_t\">37</a>]. More than 70 percent of patients with acute Oroya fever have a positive blood culture for <em>B. bacilliformis</em>; there may be a delay of more than 14 days for the organism to grow in culture. <em>B. bacilliformis</em> is fastidious and requires Columbia agar, an enriched blood medium, for growth, which occurs most readily at 25 to 28&deg;C; other <em>Bartonella</em> spp grow readily at 37&deg;C [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/39\" class=\"abstract_t\">39</a>]. Routine blood cultures are useful to evaluate for the presence of secondary bacteremia. The reliability of microscopy depends on the skill of the laboratory technician and may be associated misdiagnosis [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/40\" class=\"abstract_t\">40</a>].</p><p>The diagnosis of verruga peruana is generally based on characteristic clinical features, with or without skin biopsy; blood cultures are positive in only 10 to 15 percent of cases [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/28\" class=\"abstract_t\">28</a>]. The histologic findings consist of a highly dense proliferation of small- and large-sized blood vessels [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/41\" class=\"abstract_t\">41</a>]. Neutrophils and endothelial cells predominate in the dermis; histiocytes, plasma cells, lymphocytes, and mast cells are also variably present. Hyperkeratosis, parakeratosis, and mild acanthosis are observed in the epidermis. In some cases, Giemsa staining of a biopsy sample demonstrates characteristic cytoplasmic inclusions, referred to as Rocha-Lima inclusions [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/41\" class=\"abstract_t\">41</a>]. In addition, electron microscopy allows visualization of the <em>B. bacilliformis</em> organism [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/41\" class=\"abstract_t\">41</a>]. Phagocytized <em>B. bacilliformis</em> may be observed within neutrophils, histiocytes, <span class=\"nowrap\">and/or</span> endothelial cells [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/41,42\" class=\"abstract_t\">41,42</a>].</p><p>Serologic tests for <em>B. bacilliformis</em> infection have been developed [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/43\" class=\"abstract_t\">43</a>], including an immunoblot test that uses a sonicate of whole <em>B. bacilliformis</em> as an antigen [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/44\" class=\"abstract_t\">44</a>], and an indirect fluorescence antibody test [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/45\" class=\"abstract_t\">45</a>]. These tests have been useful in epidemiologic studies [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/43\" class=\"abstract_t\">43</a>].</p><p>Excellent results with polymerase chain reaction (PCR) techniques for diagnosis of <em>B</em>. <em>bacilliformis</em> on blood samples from patients with clinically diagnosed Oroya fever have been described [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/46\" class=\"abstract_t\">46</a>]. Among the different approaches, <em>Bartonella</em>-specific 16S rRNA PCR presents the lowest detection limit (5 colony-forming <span class=\"nowrap\">units/mcL)</span> in blood samples and dried blood spots, improving the detection of patients with low-level bacteremia [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/47\" class=\"abstract_t\">47</a>]. However, its high cost and the lack of molecular laboratories in endemic areas limits its use [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/46,48\" class=\"abstract_t\">46,48</a>]. Loop-mediated isothermal amplification, a nucleic acid amplification method, demonstrates similar sensitivity to PCR but requires less specialized equipment, enabling use in some endemic areas [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/49\" class=\"abstract_t\">49</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>South American bartonellosis may be confused with other illnesses that cause fever or cutaneous lesions. Oroya fever can mimic other infectious and tropical diseases (<a href=\"image.htm?imageKey=ID%2F93381\" class=\"graphic graphic_table graphicRef93381 \">table 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malaria and dengue share some common clinical features and similar endemic patterns with Oroya fever. (See <a href=\"topic.htm?path=clinical-manifestations-of-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">&quot;Clinical manifestations of malaria in nonpregnant adults and children&quot;</a> and <a href=\"topic.htm?path=dengue-virus-infection-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Dengue virus infection: Clinical manifestations and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oroya fever may mimic infection with <em>Salmonella typhi</em> in areas of the tropics where typhoid fever is common, particularly in patients with prominent gastrointestinal complaints. In addition, typhi and non-typhi <em>Salmonella</em> may cause secondary infection in patients with Oroya fever. (See <a href=\"topic.htm?path=epidemiology-microbiology-clinical-manifestations-and-diagnosis-of-enteric-typhoid-and-paratyphoid-fever\" class=\"medical medical_review\">&quot;Epidemiology, microbiology, clinical manifestations, and diagnosis of enteric (typhoid and paratyphoid) fever&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Viral hepatitis constitutes an important differential diagnosis in the highlands and the Amazon basin, where prevalence of both conditions is high.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some clinical features of Oroya fever overlap with those of leptospirosis. (See <a href=\"topic.htm?path=epidemiology-microbiology-clinical-manifestations-and-diagnosis-of-leptospirosis\" class=\"medical medical_review\">&quot;Epidemiology, microbiology, clinical manifestations, and diagnosis of leptospirosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bartonellosis may have features that overlap with hematologic malignancy such as acute leukemia. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-myeloid-leukemia\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia&quot;</a>.)</p><p/><p>Verruga peruana may need to be differentiated from other skin conditions, including (<a href=\"image.htm?imageKey=ID%2F93381\" class=\"graphic graphic_table graphicRef93381 \">table 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bacillary angiomatosis &ndash; Bacillary angiomatosis occurs most often in patients with HIV infection or other form of immunosuppression. (See <a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-bartonella-infections-in-hiv-infected-patients#H2\" class=\"medical medical_review\">&quot;Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients&quot;, section on 'Bacillary angiomatosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Yaws &ndash; Yaws causes papules with subsequent ulceration. Clinical diagnosis is generally straightforward in endemic areas; confirmation requires serology. (See <a href=\"topic.htm?path=yaws-bejel-and-pinta#H12097892\" class=\"medical medical_review\">&quot;Yaws, bejel, and pinta&quot;, section on 'Yaws'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pyogenic granuloma &ndash; Pyogenic granuloma is a benign vascular tumor of the skin or mucous membrane. (See <a href=\"topic.htm?path=pyogenic-granuloma-lobular-capillary-hemangioma\" class=\"medical medical_review\">&quot;Pyogenic granuloma (Lobular capillary hemangioma)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Angioma &ndash; An angioma is a capillary proliferation on the skin. (See <a href=\"topic.htm?path=overview-of-benign-lesions-of-the-skin#H8\" class=\"medical medical_review\">&quot;Overview of benign lesions of the skin&quot;, section on 'Cherry angioma'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cutaneous lymphoma &ndash; Cutaneous lymphomas are a heterogeneous group of T cell and B cell neoplasms that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. (See <a href=\"topic.htm?path=classification-of-primary-cutaneous-lymphomas\" class=\"medical medical_review\">&quot;Classification of primary cutaneous lymphomas&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Capillary malformation &ndash; Capillary malformation is a vascular malformation with nodular features that is present at birth. (See <a href=\"topic.htm?path=capillary-malformations-port-wine-stains-and-associated-syndromes\" class=\"medical medical_review\">&quot;Capillary malformations (port wine stains) and associated syndromes&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Kaposi sarcoma &ndash; Kaposi sarcoma is an angioproliferative disorder due to infection with human herpesvirus 8. (See <a href=\"topic.htm?path=classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment\" class=\"medical medical_review\">&quot;Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tuberculosis and atypical mycobacterial infection &ndash; Rapidly growing mycobacteria can cause cutaneous infection. (See <a href=\"topic.htm?path=rapidly-growing-mycobacterial-infections-mycobacteria-abscessus-chelonae-and-fortuitum\" class=\"medical medical_review\">&quot;Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prompt initiation of appropriate antimicrobial therapy is essential for patients with known or suspected <em>Bartonellosis</em> infection (<a href=\"image.htm?imageKey=ID%2F77298\" class=\"graphic graphic_table graphicRef77298 \">table 2</a>). The optimal approach to treatment is uncertain; clinical practice is based on small case series.</p><p>In vitro susceptibility testing for <em>Bartonella</em> species is difficult because the organism is fastidious; primary isolation requires up to four weeks of incubation on blood agar plates [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/50\" class=\"abstract_t\">50</a>]. Multiple antimicrobial agents are active against <em>B. bacilliformis</em> in vitro, including <a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">chloramphenicol</a>, fluoroquinolones, penicillins, cephalosporins, <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, and <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a>. <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a>, <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a>, aminoglycosides, and <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a> are not considered good treatment options against this organism since relatively high doses are required to inhibit bacterial growth [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/1,50\" class=\"abstract_t\">1,50</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Oroya fever</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For treatment of uncomplicated Oroya fever in nonpregnant adults, we favor <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a>; data for this approach are limited and largely based on observational data and clinical experience [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/50\" class=\"abstract_t\">50</a>]. There are no well-designed clinical trials that have evaluated possible resistance of <em>B. bacilliformis</em> to ciprofloxacin, but limited in vitro data has suggested intrinsic resistance and reduced susceptibility to nalidixic acid and ciprofloxacin among some isolates [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/51-53\" class=\"abstract_t\">51-53</a>]. An antimicrobial susceptibility assessment of 100 strains isolated from endemic areas in Peru demonstrated a 26 percent resistance to ciprofloxacin [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/54\" class=\"abstract_t\">54</a>]; therefore, for treatment of severe or persistent disease, we favor administering the combination regimen of <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a> and ciprofloxacin [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/55\" class=\"abstract_t\">55</a>].</p><p>Previously, <a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">chloramphenicol</a> was a preferred agent for treatment of Oroya fever [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/28,56,57\" class=\"abstract_t\">28,56,57</a>]; we favor it as an alternative treatment choice [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/58\" class=\"abstract_t\">58</a>]. It has activity against <em>B. bacilliformis </em>as well as <em>Salmonella</em>, a common secondary infection [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/56,59\" class=\"abstract_t\">56,59</a>]. However, treatment failure with persistent <em>Bartonella</em> bacteremia and relapse after treatment has been described among patients treated with chloramphenicol [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/28,60\" class=\"abstract_t\">28,60</a>]. In addition, successful treatment of Oroya fever with chloramphenicol does not eliminate risk for development of verruga peruana [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/50\" class=\"abstract_t\">50</a>]. If chloramphenicol is used, coadministration of another antibiotic (such as a beta-lactam agent) is warranted.</p><p>For treatment of uncomplicated Oroya fever in children and pregnant women, we favor amoxicillin-clavulanic acid; in severe cases, we favor treatment with <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a> [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/55\" class=\"abstract_t\">55</a>]. <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">Ciprofloxacin</a> and <a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">chloramphenicol</a> should be avoided in pregnancy [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/61\" class=\"abstract_t\">61</a>].</p><p><a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">Dexamethasone</a> may be administered for patients with severe neurologic complications to reduce cerebral edema. Blood transfusion may be warranted in cases of severe anemia [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/62\" class=\"abstract_t\">62</a>].</p><p>Dosing is summarized in the table (<a href=\"image.htm?imageKey=ID%2F77298\" class=\"graphic graphic_table graphicRef77298 \">table 2</a>).</p><p>With successful therapy, clinical response is generally observed promptly, including defervescence and resolution of hemolysis.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Verruga peruana</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We favor <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> for treatment of verruga peruana in adults, children, and pregnant women [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/39,55\" class=\"abstract_t\">39,55</a>]. Azithromycin has been shown to have clinical efficacy comparable to that of <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/5\" class=\"abstract_t\">5</a>].</p><p><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> is an acceptable alternative agent for treatment of verruga peruana [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/28,57\" class=\"abstract_t\">28,57</a>], although its use as monotherapy may lead to rapid development of resistance and treatment failures with rifampin have been described [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/63\" class=\"abstract_t\">63</a>]. In addition, the verruga zone contains regions with a high incidence of tuberculosis, and rifampin monotherapy may lead to mycobacterial resistance. Intramuscular <a href=\"topic.htm?path=streptomycin-drug-information\" class=\"drug drug_general\">streptomycin</a> and oral rifampin have comparable efficacy; rifampin is favored over streptomycin given difficulty with adherence to intramuscular therapy [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/28\" class=\"abstract_t\">28</a>].</p><p><a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">Ciprofloxacin</a> is also an acceptable alternative agent for treatment of verruga peruana [<a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/39,50\" class=\"abstract_t\">39,50</a>]. Its efficacy appears to be similar to that of <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a>, although there is less clinical experience with this agent for treatment of verruga peruana, and it is not appropriate for treatment of pregnant women.</p><p><a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">Chloramphenicol</a> is not effective for treatment of verruga peruana.</p><p>Dosing is summarized in the table (<a href=\"image.htm?imageKey=ID%2F77298\" class=\"graphic graphic_table graphicRef77298 \">table 2</a>).</p><p>With successful therapy, the skin lesions typically resolve within one month with no residual scarring.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bartonellosis is an infection caused by <em>Bartonella bacilliformis</em> that is transmitted by phlebotomine sand flies. The classic biphasic illness is characterized by an initial febrile phase, known as Oroya fever, followed by a secondary phase characterized by development of skin lesions, known as verruga peruana. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bartonellosis is endemic to the &quot;verruga zone,&quot; a region in the Andes Mountains of Peru, Columbia, and Ecuador. Oroya fever occurs most frequently among tourists and transient workers who are immunologically na&iuml;ve to <em>B. bacilliformis</em>, while verruga peruana occurs most frequently among individuals native to the verruga zone. (See <a href=\"#H6660551\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The acute, or hematic, phase generally begins on average two months after inoculation, usually with insidious onset of mild fever, headache, anorexia, and malaise. This stage lasts between two to four weeks; mortality is low in patients who receive appropriate antimicrobial therapy. Anemia develops due to parasitic infection of red blood cells and cells of the reticuloendothelial system, with subsequent clearance of parasitized cells from the circulation. (See <a href=\"#H7\" class=\"local\">'Acute phase (Oroya fever)'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The eruptive, or verruga, phase occurs after organisms invade capillary endothelial cells and induce cellular proliferation, producing hemangioma-like nodules in the skin and mucous membranes. Verruga peruana can appear weeks or months after the patient has apparently recovered from Oroya fever. However, most patients with verruga peruana do not have a clear antecedent history of febrile illness. (See <a href=\"#H8\" class=\"local\">'Eruptive phase (verruga peruana)'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of Oroya fever is made by blood culture or by identification of <em>B. bacilliformis</em> organisms on a Giemsa-stained blood smear. The diagnosis of verruga peruana is generally based on characteristic clinical features and serology and confirmed by histopathologic analysis. (See <a href=\"#H16718024\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> for treatment of uncomplicated Oroya fever in nonpregnant adults (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>); for treatment of severe or persistent disease, we favor administration of ciprofloxacin in combination with <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a>. For treatment of uncomplicated Oroya fever in children and pregnant women, we favor treatment with amoxicillin-clavulanic acid; in severe cases, we favor treatment with ceftriaxone. Dosing is summarized in the table (<a href=\"image.htm?imageKey=ID%2F77298\" class=\"graphic graphic_table graphicRef77298 \">table 2</a>). (See <a href=\"#H14\" class=\"local\">'Oroya fever'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> for treatment of verruga peruana in adults, pregnant women, and children (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>); <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> are alternative choices. Dosing is summarized in the table (<a href=\"image.htm?imageKey=ID%2F77298\" class=\"graphic graphic_table graphicRef77298 \">table 2</a>). (See <a href=\"#H15\" class=\"local\">'Verruga peruana'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/1\" class=\"nounderline abstract_t\">Maguina VC, Ugarte-Gil C, Brena CP, et al. Update of Carrion's disease. Rev Med Hered 2008; 19:36.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/2\" class=\"nounderline abstract_t\">Minnick MF, Anderson BE, Lima A, et al. Oroya fever and verruga peruana: bartonelloses unique to South America. PLoS Negl Trop Dis 2014; 8:e2919.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/3\" class=\"nounderline abstract_t\">Alexander B. A review of bartonellosis in Ecuador and Colombia. Am J Trop Med Hyg 1995; 52:354.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/4\" class=\"nounderline abstract_t\">Laval RE. Daniel Alcides Carrion. Rev Chilena Infectol 2003; 20:36.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/5\" class=\"nounderline abstract_t\">Sanchez Clemente N, Ugarte-Gil CA, Sol&oacute;rzano N, et al. Bartonella bacilliformis: a systematic review of the literature to guide the research agenda for elimination. PLoS Negl Trop Dis 2012; 6:e1819.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/6\" class=\"nounderline abstract_t\">Andre R, Korves C, Fernandez R, et al. Host feeding behavior of Lutzomyia verrucarum in and around the house of bartonellosis patients in Per&uacute;. Am J Trop Med Hyg 1998; 59:212.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/7\" class=\"nounderline abstract_t\">Caceres AG. [Geographic distribution of Lutzomyia verrucarum (Townsend, 1913) (Diptera, Psychodidae, Phlebotominae), vector of human bartonellosis in Peru]. Rev Inst Med Trop Sao Paulo 1993; 35:485.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/8\" class=\"nounderline abstract_t\">Caceres AG, Galati EA, Le Pont F, Velasquez C. Possible role of Lutzomyia maranonensis and Lutzomyia robusta (Diptera: Psychodidae) as vectors of human bartonellosis in three provinces of region nor Oriental del Mara&ntilde;on, Peru. Rev Inst Med Trop Sao Paulo 1997; 39:51.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/9\" class=\"nounderline abstract_t\">Ellis BA, Rotz LD, Leake JA, et al. An outbreak of acute bartonellosis (Oroya fever) in the Urubamba region of Peru, 1998. Am J Trop Med Hyg 1999; 61:344.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/10\" class=\"nounderline abstract_t\">Chamberlin J, Laughlin LW, Romero S, et al. Epidemiology of endemic Bartonella bacilliformis: a prospective cohort study in a Peruvian mountain valley community. J Infect Dis 2002; 186:983.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/11\" class=\"nounderline abstract_t\">Amano Y, Rumbea J, Knobloch J, et al. Bartonellosis in Ecuador: serosurvey and current status of cutaneous verrucous disease. Am J Trop Med Hyg 1997; 57:174.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/12\" class=\"nounderline abstract_t\">Tuya XL, Escalante-Kanashiro R, Tinco C, et al. Possible vertical transmission of Bartonella bacilliformis in Peru. Am J Trop Med Hyg 2015; 92:126.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/13\" class=\"nounderline abstract_t\">Huarcaya-Castilla E, Chinga-Alayo E, Chavez-Paz J, et al. Influence of El Ni&ntilde;o Phenomenon in the epidemiology of human bartonellosis in the Departments of Ancash and Cusco between 1996 and 1999. Rev Med Hered 2004; 15:4.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/14\" class=\"nounderline abstract_t\">Chinga-Alayo E, Huarcaya E, Nasarre C, et al. The influence of climate on the epidemiology of bartonellosis in Ancash, Peru. Trans R Soc Trop Med Hyg 2004; 98:116.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/15\" class=\"nounderline abstract_t\">Eremeeva ME, Gerns HL, Lydy SL, et al. Bacteremia, fever, and splenomegaly caused by a newly recognized bartonella species. N Engl J Med 2007; 356:2381.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/16\" class=\"nounderline abstract_t\">Diniz PP, Morton BA, Tngrian M, et al. Infection of domestic dogs in peru by zoonotic bartonella species: a cross-sectional prevalence study of 219 asymptomatic dogs. PLoS Negl Trop Dis 2013; 7:e2393.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/17\" class=\"nounderline abstract_t\">Caceres AG, Padilla Rojas CP, Arias Stella J, et al. Detection of Bartonella spp and Rickettsia spp in fleas, ticks, and lice collected in rural areas of Peru. Rev Peru Biol 2013; 20:165.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/18\" class=\"nounderline abstract_t\">Mullins KE, Hang J, Jiang J, et al. Description of Bartonella ancashensis sp. nov., isolated from the blood of two patients with verruga peruana. Int J Syst Evol Microbiol 2015; 65:3339.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/19\" class=\"nounderline abstract_t\">Hang J, Mullins KE, Clifford RJ, et al. Complete Genome Sequence of Bartonella ancashensis Strain 20.00, Isolated from the Blood of a Patient with Verruga Peruana. Genome Announc 2015; 3.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/20\" class=\"nounderline abstract_t\">Mullins KE, Hang J, Clifford RJ, et al. Whole-Genome Analysis of Bartonella ancashensis, a Novel Pathogen Causing Verruga Peruana, Rural Ancash Region, Peru. Emerg Infect Dis 2017; 23:430.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/21\" class=\"nounderline abstract_t\">Merrell DS, Falkow S. Frontal and stealth attack strategies in microbial pathogenesis. Nature 2004; 430:250.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/22\" class=\"nounderline abstract_t\">Harms A, Dehio C. Intruders below the radar: molecular pathogenesis of Bartonella spp. Clin Microbiol Rev 2012; 25:42.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/23\" class=\"nounderline abstract_t\">Huarcaya E, Best I, Rodriguez-Tafur J, et al. Cytokines and T-Lymphocute count in patients in the acute and chronic phases of Bartonella bacilliformis infection in an endemic area in peru: a pilot study. Rev Inst Med Trop Sao Paulo 2011; 53:149.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/24\" class=\"nounderline abstract_t\">Dehio C, Lanz C, Pohl R, et al. Bartonella schoenbuchii sp. nov., isolated from the blood of wild roe deer. Int J Syst Evol Microbiol 2001; 51:1557.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/25\" class=\"nounderline abstract_t\">Sander A, Zagrosek A, Bredt W, et al. Characterization of Bartonella clarridgeiae flagellin (FlaA) and detection of antiflagellin antibodies in patients with lymphadenopathy. J Clin Microbiol 2000; 38:2943.</a></li><li class=\"breakAll\">Dehio C, Maguina C, Walker DH. Bartonelloses. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant R, Walker D, Weller, P (Eds), Saunders Elsevier, Philadelphia 2011. p.265.</li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/27\" class=\"nounderline abstract_t\">Bass JW, Vincent JM, Person DA. The expanding spectrum of Bartonella infections: II. Cat-scratch disease. Pediatr Infect Dis J 1997; 16:163.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/28\" class=\"nounderline abstract_t\">Maguina C, Garcia PJ, Gotuzzo E, et al. Bartonellosis (Carri&oacute;n's disease) in the modern era. Clin Infect Dis 2001; 33:772.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/29\" class=\"nounderline abstract_t\">Kosek M, Lavarello R, Gilman RH, et al. Natural history of infection with Bartonella bacilliformis in a nonendemic population. J Infect Dis 2000; 182:865.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/30\" class=\"nounderline abstract_t\">Ihler GM. Bartonella bacilliformis: dangerous pathogen slowly emerging from deep background. FEMS Microbiol Lett 1996; 144:1.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/31\" class=\"nounderline abstract_t\">Montoya M, Maguina C, Vigo B, et al. Brote epidemico de enfermedad de Carrion en el Valle Sagrado de los Incas (Cuzco). Bol Soc Peru Med Int 1998; 11:170.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/32\" class=\"nounderline abstract_t\">Bre&ntilde;a CJ, Magui&ntilde;a VC, Hernandez DH, et al. Bartonelosis aguda en ni&ntilde;os: Estudio de 32 casos en el Instituto Especializado de Salud del Ni&ntilde;o y el Hospital Nacional Cayetano Heredia (Per&iacute;odo 1993-2003). Rev Med Hered 2006; 17:122.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/33\" class=\"nounderline abstract_t\">Magui&ntilde;a VC, Pe&ntilde;a CR, Ponce AM, et al. Manifestaciones cl&iacute;nicas y complicaciones de la fase aguda de bartonelosis o Fiebre de la Oroya en pacientes atendidos en el Hospital Nacional Cayetano Heredia. Rev Med Hered 2008; 19:87.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/34\" class=\"nounderline abstract_t\">Huerta A, Salas M, Yarinsueca J, Magui&ntilde;a C. [Carri&oacute;n's disease complicated with severe acute leptospirosis: a case report]. Rev Peru Med Exp Salud Publica 2014; 31:380.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/35\" class=\"nounderline abstract_t\">Lopez-de-Guimaraes D, Menacho-Lopez J, Norabuena-Penadillo R, et al. Purpura trombocitop&eacute;nica y bartonelosis aguda (enfermedad de Carri&oacute;n) en Huaraz, Peru. Acta Med Peru 2006; 23:6.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/36\" class=\"nounderline abstract_t\">Maguina VC, Ordaya EE, Ugarte-Gil C, et al. Compromiso cardiovascular en la fase aguda de la enfermedad de Carri&oacute;n o bartonelosis humana: 20 a&ntilde;os de experiencia en Hospital Nacional Cayetano Heredia. Acta Med Peru 2008; 25:30.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/37\" class=\"nounderline abstract_t\">RICKETTS WE. Clinical manifestations of Carri&oacute;n's disease. Arch Intern Med (Chic) 1949; 84:751.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/38\" class=\"nounderline abstract_t\">Maguina C, Cok J, Gilman R, et al. Estudio prospectivo de la verruga peruana recurrente. Dermatol Peru 2003; 13:189.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/39\" class=\"nounderline abstract_t\">Magui&ntilde;a C, Gotuzzo E. Bartonellosis. New and old. Infect Dis Clin North Am 2000; 14:1.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/40\" class=\"nounderline abstract_t\">Cornejo A, Gomes C, Suarez L, et al. An unidentified cluster of infection in the Peruvian Amazon region. J Infect Dev Ctries 2015; 9:524.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/41\" class=\"nounderline abstract_t\">Arias-Stella J, Lieberman PH, Erlandson RA, Arias-Stella J Jr. Histology, immunohistochemistry, and ultrastructure of the verruga in Carrion's disease. Am J Surg Pathol 1986; 10:595.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/42\" class=\"nounderline abstract_t\">Bhutto AM, Nonaka S, Hashiguchi Y, Gomez EA. Histopathological and electron microscopical features of skin lesions in a patient with bartonellosis (verruga peruana). J Dermatol 1994; 21:178.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/43\" class=\"nounderline abstract_t\">Knobloch J, Solano L, Alvarez O, Delgado E. Antibodies to Bartonella bacilliformis as determined by fluorescence antibody test, indirect haemagglutination and ELISA. Trop Med Parasitol 1985; 36:183.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/44\" class=\"nounderline abstract_t\">Mallqui V, Speelmon EC, Ver&aacute;stegui M, et al. Sonicated diagnostic immunoblot for bartonellosis. Clin Diagn Lab Immunol 2000; 7:1.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/45\" class=\"nounderline abstract_t\">Chamberlin J, Laughlin L, Gordon S, et al. Serodiagnosis of Bartonella bacilliformis infection by indirect fluorescence antibody assay: test development and application to a population in an area of bartonellosis endemicity. J Clin Microbiol 2000; 38:4269.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/46\" class=\"nounderline abstract_t\">del Valle Mendoza J, Silva Caso W, Tinco Valdez C, et al. Diagnosis of Carrion's disease by direct blood PCR in thin blood smear negative samples. PLoS One 2014; 9:e92283.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/47\" class=\"nounderline abstract_t\">Gomes C, Martinez-Puchol S, Pons MJ, et al. Evaluation of PCR Approaches for Detection of Bartonella bacilliformis in Blood Samples. PLoS Negl Trop Dis 2016; 10:e0004529.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/48\" class=\"nounderline abstract_t\">Maguina C, Romero I, Soto N, et al. Historia natural de la fase eruptiva de la Verruga Peruana y la importancia de la prueba de western blot, reporte preliminar. F Dermatol 2002; 13:36.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/49\" class=\"nounderline abstract_t\">Angkasekwinai N, Atkins EH, Johnson RN, et al. Rapid and sensitive detection of Bartonella bacilliformis in experimentally infected sand flies by loop-mediated isothermal amplification (LAMP) of the Pap31 gene. PLoS Negl Trop Dis 2014; 8:e3342.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/50\" class=\"nounderline abstract_t\">Rolain JM, Brouqui P, Koehler JE, et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48:1921.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/51\" class=\"nounderline abstract_t\">Angelakis E, Biswas S, Taylor C, et al. Heterogeneity of susceptibility to fluoroquinolones in Bartonella isolates from Australia reveals a natural mutation in gyrA. J Antimicrob Chemother 2008; 61:1252.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/52\" class=\"nounderline abstract_t\">del Valle LJ, Flores L, Vargas M, et al. Bartonella bacilliformis, endemic pathogen of the Andean region, is intrinsically resistant to quinolones. Int J Infect Dis 2010; 14:e506.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/53\" class=\"nounderline abstract_t\">Espinoza-Culupu A, Quispe-Gaspar R, Jaramillo M. Molecular characterization of quinolones resistance determining region (QRDR) of Bartonella bacilliformis topoisomerasa IV in clinical isolates. Rev Peru Biol 2014; 21:89.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/54\" class=\"nounderline abstract_t\">Mendoza-Mujica G, Flores-Le&oacute;n D. [Antimicrobial resistance of Bartonella bacilliformis strains from regions endemic to bartonellosis in Peru]. Rev Peru Med Exp Salud Publica 2015; 32:659.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/55\" class=\"nounderline abstract_t\">Tarazona A, Maguina C, Lopez de Guimaraes, et al. Terapia antibi&oacute;tica para el manejo de la Bartonellosis o enfermedad de Carri&oacute;n en el Per&uacute;. Rev Peru Med Exp Salud Publica 2006; 23:188.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/56\" class=\"nounderline abstract_t\">URTEAGA O, PAYNE EH. Treatment of the acute febrile phase of Carri&oacute;n's disease with chloramphenicol. Am J Trop Med Hyg 1955; 4:507.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/57\" class=\"nounderline abstract_t\">Arroyo A. Treatment outlines for non-complicated Carrion's disease in Caraz, Peru. Anales de la Facultad de Medecina 2008; 69:7.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/58\" class=\"nounderline abstract_t\">Gray GC, Johnson AA, Thornton SA, et al. An epidemic of Oroya fever in the Peruvian Andes. Am J Trop Med Hyg 1990; 42:215.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/59\" class=\"nounderline abstract_t\">CUADRA M. Salmonellosis complication in human bartonellosis. Tex Rep Biol Med 1956; 14:97.</a></li><li class=\"breakAll\">Pachas P, Rojas Y, Solorzano N, et al. Persistance of bacteremia by Bartonella bacilliformis post treatment with chloramphenicol. Abstract presented at the ASTHM 55th Annual Meeting, 2006, Atlanta, Georgia, USA.  </li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/61\" class=\"nounderline abstract_t\">Amstey MS. Chloramphenicol therapy in pregnancy. Clin Infect Dis 2000; 30:237.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/62\" class=\"nounderline abstract_t\">HODGSON CH. The treatment of Carrion's disease with large transfusions. Am J Trop Med Hyg 1947; 27:69.</a></li><li><a href=\"https://www.uptodate.com/contents/south-american-bartonellosis-oroya-fever-and-verruga-peruana/abstract/63\" class=\"nounderline abstract_t\">Maguina Vargas C. Bartonellosis o enfermedad de carrion. Nuevos aspectos de una vieja enfermedad. AFA Editores Importadores, Lima, Peru 1998; :7.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5516 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H16\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H14405285\" id=\"outline-link-H14405285\">HISTORY</a></li><li><a href=\"#H6660551\" id=\"outline-link-H6660551\">EPIDEMIOLOGY</a></li><li><a href=\"#H14405321\" id=\"outline-link-H14405321\">MICROBIOLOGY</a></li><li><a href=\"#H14405361\" id=\"outline-link-H14405361\">PATHOGENESIS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Acute phase (Oroya fever)</a><ul><li><a href=\"#H6660793\" id=\"outline-link-H6660793\">- Complications</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">Eruptive phase (verruga peruana)</a></li></ul></li><li><a href=\"#H16718024\" id=\"outline-link-H16718024\">DIAGNOSIS</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">TREATMENT</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">Oroya fever</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Verruga peruana</a></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/5516|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/66284\" class=\"graphic graphic_picture\">- Miliary lesions bartonellos</a></li><li><a href=\"image.htm?imageKey=ID/76799\" class=\"graphic graphic_picture\">- Mular lesion bartonellosis</a></li><li><a href=\"image.htm?imageKey=ID/60673\" class=\"graphic graphic_picture\">- Nodular lesions bartonellos</a></li><li><a href=\"image.htm?imageKey=ID/58621\" class=\"graphic graphic_picture\">- Giemsa stain bartonellosis</a></li></ul></li><li><div id=\"ID/5516|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/93381\" class=\"graphic graphic_table\">- Differential diagnosis of South American bartonellosis</a></li><li><a href=\"image.htm?imageKey=ID/77298\" class=\"graphic graphic_table\">- Treatment for bartonellosis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=aids-related-kaposi-sarcoma-staging-and-treatment\" class=\"medical medical_review\">AIDS-related Kaposi sarcoma: Staging and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=capillary-malformations-port-wine-stains-and-associated-syndromes\" class=\"medical medical_review\">Capillary malformations (port wine stains) and associated syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment\" class=\"medical medical_review\">Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classification-of-primary-cutaneous-lymphomas\" class=\"medical medical_review\">Classification of primary cutaneous lymphomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">Clinical manifestations of malaria in nonpregnant adults and children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-myeloid-leukemia\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dengue-virus-infection-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Dengue virus infection: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-bartonella-infections-in-hiv-infected-patients\" class=\"medical medical_review\">Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-microbiology-clinical-manifestations-and-diagnosis-of-enteric-typhoid-and-paratyphoid-fever\" class=\"medical medical_review\">Epidemiology, microbiology, clinical manifestations, and diagnosis of enteric (typhoid and paratyphoid) fever</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-microbiology-clinical-manifestations-and-diagnosis-of-leptospirosis\" class=\"medical medical_review\">Epidemiology, microbiology, clinical manifestations, and diagnosis of leptospirosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-benign-lesions-of-the-skin\" class=\"medical medical_review\">Overview of benign lesions of the skin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pyogenic-granuloma-lobular-capillary-hemangioma\" class=\"medical medical_review\">Pyogenic granuloma (Lobular capillary hemangioma)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rapidly-growing-mycobacterial-infections-mycobacteria-abscessus-chelonae-and-fortuitum\" class=\"medical medical_review\">Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=yaws-bejel-and-pinta\" class=\"medical medical_review\">Yaws, bejel, and pinta</a></li></ul></div></div>","javascript":null}